ARQT SEC Filing News — Arcutis Biotherapeutics, Inc.

Latest SEC filings for Arcutis Biotherapeutics, Inc. (ARQT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-15.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as…
Sector: Healthcare Industry: Biotechnology Market Cap: $4.1B CIK: 1787306
20
Total Filings
0
Bullish Classifications
12
Bearish Classifications
11
Insider Transactions
0
Material Events (8-K)
0
Periodic Reports
Rule-based classifications for ARQT currently lean bearish. Of the 20 filing records displayed, 12 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
ARQT Filing Activity Snapshot 2026-08-05 — 2026-10-15
Insider Transactions (Form 4)
0 buys vs 11 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$8.55M
Larry Todd Edwards · 2026-09-16
341,980 shares · Form 144
Form 144 Notices
9
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Arcutis Biotherapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 11 open-market sale. 11 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×11
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Insider Selling 2026-09-18

ARQT insider Matsuda Masaru (See Remarks) sold 3,674 shares (~$91.9K)

Matsuda Masaru, listed as See Remarks at Arcutis Biotherapeutics, Inc., reported an open-market sale of 3,674 ARQT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 3,674 $25.00 $91.9K
Filing: Form 4 (Insider Transaction) Insider: Matsuda Masaru (See Remarks) Shares: 3,674 Est. Value: $91.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-17

ARQT insider Welgus Howard G. (Director) sold 4,730 shares (~$114.4K)

Welgus Howard G., listed as Director at Arcutis Biotherapeutics, Inc., reported an open-market sale of 4,730 ARQT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 822 $6.52 $5.4K
M Option exercise 1,019 $7.51 $7.7K
M Option exercise 2,255 $8.63 $19.5K
S Open-market sale 4,730 $24.18 $114.4K
M Option exercise derivative · Stock Option (right to buy) 822 — —
M Option exercise derivative · Stock Option (right to buy) 1,019 — —
M Option exercise derivative · Stock Option (right to buy) 2,255 — —
Filing: Form 4 (Insider Transaction) Insider: Welgus Howard G. (Director) Shares: 4,730 Est. Value: $114.4K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-10

ARQT insider Matsuda Masaru (See Remarks) sold 9,989 shares (~$250.0K)

Matsuda Masaru, listed as See Remarks at Arcutis Biotherapeutics, Inc., reported an open-market sale of 9,989 ARQT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 9,989 $25.03 $250.0K
Filing: Form 4 (Insider Transaction) Insider: Matsuda Masaru (See Remarks) Shares: 9,989 Est. Value: $250.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-28

ARQT insider Curran Terrie (Director) sold 38,200 shares (~$956.1K)

Curran Terrie, listed as Director at Arcutis Biotherapeutics, Inc., reported an open-market sale of 38,200 ARQT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 11,148 $7.51 $83.7K
S Open-market sale 11,148 $25.03 $279.0K
M Option exercise 27,052 $8.63 $233.5K
S Open-market sale 27,052 $25.03 $677.1K
M Option exercise derivative · Stock Option (right to buy) 11,148 — —
M Option exercise derivative · Stock Option (right to buy) 27,052 — —
Filing: Form 4 (Insider Transaction) Insider: Curran Terrie (Director) Shares: 38,200 Est. Value: $956.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-24

ARQT insider Curran Terrie (Director) sold 1,072 shares (~$27.9K)

Curran Terrie, listed as Director at Arcutis Biotherapeutics, Inc., reported an open-market sale of 1,072 ARQT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 1,072 $7.51 $8.1K
S Open-market sale 1,072 $26.04 $27.9K
M Option exercise derivative · Stock Option (right to buy) 1,072 — —
Filing: Form 4 (Insider Transaction) Insider: Curran Terrie (Director) Shares: 1,072 Est. Value: $27.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-21

ARQT insider Burnett Patrick (See Remarks) sold 1,697 shares (~$45.8K)

Burnett Patrick, listed as See Remarks at Arcutis Biotherapeutics, Inc., reported an open-market sale of 1,697 ARQT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,697 $27.00 $45.8K
Filing: Form 4 (Insider Transaction) Insider: Burnett Patrick (See Remarks) Shares: 1,697 Est. Value: $45.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-19

ARQT insider Welgus Howard G. (Director) sold 4,730 shares (~$123.8K)

Welgus Howard G., listed as Director at Arcutis Biotherapeutics, Inc., reported an open-market sale of 4,730 ARQT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 822 $6.52 $5.4K
M Option exercise 1,019 $7.51 $7.7K
M Option exercise 2,255 $8.63 $19.5K
S Open-market sale 4,730 $26.18 $123.8K
M Option exercise derivative · Stock Option (right to buy) 822 — —
M Option exercise derivative · Stock Option (right to buy) 1,019 — —
M Option exercise derivative · Stock Option (right to buy) 2,255 — —
Filing: Form 4 (Insider Transaction) Insider: Welgus Howard G. (Director) Shares: 4,730 Est. Value: $123.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-13

ARQT insider Burnett Patrick (See Remarks) sold 15,000 shares (~$394.9K)

Burnett Patrick, listed as See Remarks at Arcutis Biotherapeutics, Inc., reported an open-market sale of 15,000 ARQT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 8,300 $3.64 $30.2K
S Open-market sale 8,300 $26.52 $220.1K
M Option exercise 6,700 $3.64 $24.4K
S Open-market sale 6,700 $26.08 $174.8K
M Option exercise derivative · Stock Option (right to buy) 8,300 — —
M Option exercise derivative · Stock Option (right to buy) 6,700 — —
Filing: Form 4 (Insider Transaction) Insider: Burnett Patrick (See Remarks) Shares: 15,000 Est. Value: $394.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-05

ARQT insider Burnett Patrick (See Remarks) sold 955 shares (~$24.9K)

Burnett Patrick, listed as See Remarks at Arcutis Biotherapeutics, Inc., reported an open-market sale of 955 ARQT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 955 $26.12 $24.9K
Filing: Form 4 (Insider Transaction) Insider: Burnett Patrick (See Remarks) Shares: 955 Est. Value: $24.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-05

ARQT insider Matsuda Masaru (See Remarks) sold 1,230 shares (~$32.1K)

Matsuda Masaru, listed as See Remarks at Arcutis Biotherapeutics, Inc., reported an open-market sale of 1,230 ARQT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,230 $26.12 $32.1K
Filing: Form 4 (Insider Transaction) Insider: Matsuda Masaru (See Remarks) Shares: 1,230 Est. Value: $32.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-05

ARQT insider Watanabe Todd (Director, See Remarks) sold 4,375 shares (~$114.3K)

Watanabe Todd, listed as Director, See Remarks at Arcutis Biotherapeutics, Inc., reported an open-market sale of 4,375 ARQT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 4,375 $26.12 $114.3K
Filing: Form 4 (Insider Transaction) Insider: Watanabe Todd (Director, See Remarks) Shares: 4,375 Est. Value: $114.3K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 9 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Arcutis Biotherapeutics, Inc. has 9 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-15

ARQT Form 144 filed for proposed insider sale by Howard Welgus (4,728 shares) ~$127.3K

Howard Welgus filed a Form 144 with the SEC indicating intent to sell ARQT (Arcutis Biotherapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Howard Welgus Shares: 4,728 Est. Value: $127.3K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-09-16

ARQT Form 144 filed for proposed insider sale by Larry Todd Edwards (341,980 shares) ~$8.55M

Larry Todd Edwards filed a Form 144 with the SEC indicating intent to sell ARQT (Arcutis Biotherapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Larry Todd Edwards Shares: 341,980 Est. Value: $8.55M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-15

ARQT Form 144 filed for proposed insider sale by Howard Welgus (4,730 shares) ~$114.4K

Howard Welgus filed a Form 144 with the SEC indicating intent to sell ARQT (Arcutis Biotherapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Howard Welgus Shares: 4,730 Est. Value: $114.4K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-08

ARQT Form 144 filed for proposed insider sale by Masaru Matsuda (13,663 shares) ~$341.9K

Masaru Matsuda filed a Form 144 with the SEC indicating intent to sell ARQT (Arcutis Biotherapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Masaru Matsuda Shares: 13,663 Est. Value: $341.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-27

ARQT Form 144 filed for proposed insider sale by Terrie Curran (38,200 shares) ~$956.1K

Terrie Curran filed a Form 144 with the SEC indicating intent to sell ARQT (Arcutis Biotherapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Terrie Curran Shares: 38,200 Est. Value: $956.1K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-20

ARQT Form 144 filed for proposed insider sale by Terrie Curran (1,072 shares) ~$27.9K

Terrie Curran filed a Form 144 with the SEC indicating intent to sell ARQT (Arcutis Biotherapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Terrie Curran Shares: 1,072 Est. Value: $27.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-19

ARQT Form 144 filed for proposed insider sale by Patrick Burnett (1,697 shares) ~$45.8K

Patrick Burnett filed a Form 144 with the SEC indicating intent to sell ARQT (Arcutis Biotherapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Patrick Burnett Shares: 1,697 Est. Value: $45.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-17

ARQT Form 144 filed for proposed insider sale by Howard Welgus (4,730 shares) ~$123.8K

Howard Welgus filed a Form 144 with the SEC indicating intent to sell ARQT (Arcutis Biotherapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Howard Welgus Shares: 4,730 Est. Value: $123.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-11

ARQT Form 144 filed for proposed insider sale by Patrick Burnett (15,000 shares) ~$397.8K

Patrick Burnett filed a Form 144 with the SEC indicating intent to sell ARQT (Arcutis Biotherapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Patrick Burnett Shares: 15,000 Est. Value: $397.8K
View on SEC EDGAR → Open Filing Document →

How we classify Arcutis Biotherapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on ARQT. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — ARQT SEC Filings

More Tools for ARQT

ARQT Full Stock Analysis ARQT Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper ARQT analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the ARQT stock analysis page.

ARQT Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer